Table 2.
Integrity of first-line chemotherapeutic regimens and cumulative doses
| Integrity and cumulative doses | THP group (n=47) | DOX group (n=49) | P value |
|---|---|---|---|
| Integrity of chemotherapeutic regimens | |||
| Patients receiving a reduced dose | 4 (8.5%) | 4 (8.2%) | 0.62 |
| Patients transferred to second-line chemotherapy | 0 (0%) | 2 (4.1%) | 0.258 |
| Cumulative doses | |||
| HDMTX (g/m2) | 52.3 ± 4.5 | 52.2 ± 5.0 | 0.957 |
| DDP (mg/m2) | 527.7 ± 49.8 | 524.5 ± 52.2 | 0.762 |
| IFO (g/m2) | 52.8 ± 5.0 | 52.2 ± 5.9 | 0.641 |
| THP or DOX (mg/m2) | 313.2 ± 27.9 | 390.6 ± 37.2 | <0.001 |
Continuous variables are presented as means ± standard deviations (SD), and categorical data are presented as numbers (percentages). Differences between the two groups were analyzed by χ2 test or independent-samples t-test according to the data distribution. SD, standard deviation, HDMTX, high-dose methotrexate; DDP, cisplatin; IFO, ifosfamide; THP, pirarubicin; DOX, doxorubicin.